Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...

Novo Nordisk ADR (NYSE: NVO) currently trades at $89 per share, nearly 40% below its peak level of over $145 seen in June of ...

Amidst a race with its competitors to produce the next smash-hit weight loss drug, Novo Nordisk 's ( NVO -1.51%) stock ...

Exercise includes cardio and strength training, which together support heart health, healthy blood sugar levels, and weight ...

The European Union's drug regulator said it would assess two new Danish studies that link Novo Nordisk's popular diabetes ...

Denmark's drug regulator asks EMA to investigate potential link between Novo Nordisk's diabetes drug Ozempic and rare eye ...

CEO's use of Eli Lilly's (LLY) weight loss drug Mounjaro over Novo Nordisk's (NVO) rival product, Ozempic. Read more here.

Danish health authorities said on Monday they would ask the European Union's drug regulator to review the findings of two ...

The Ozempic maker's stock tanked after its highly anticipated CagriSema drug trial showed an average of 22.7% weight loss, ...

New studies link diabetes drug Ozempic to increased risk of NAION, a rare eye condition causing vision loss. Danish Medicines ...

A vision-threatening eye condition may be linked to Ozempic. Meanwhile, Nearly 80% of doctors are using telemedicine weekly, ...

Novo Nordisk (NVO) released mixed clinical-trial results for its potential Ozempic successor on Friday, leaving Wall Street ...